Luyện nói tiếng Anh bằng Shadowing qua video: Accurately Diagnosing the Soft Tissue Sarcoma

You know, as our lead surgeon and one of the lead surgeons in the world,

⏸ Tạm dừng

Tốc độ:

148 câu

Nếu các câu quá ngắn hoặc quá dài, hãy bấm Edit để chỉnh sửa.

You know, as our lead surgeon and one of the lead surgeons in the world,

I think it's always, you know,

very important that our surgical colleagues are dramatically involved in the treatment of sarcoma

because usually you're the gatekeeper in the entrance of a lot of this.

And so, you know, I think it would be good to ask you what your typical workup is for a patient

is suspected of having a sarcoma.

Sure, thanks, Brian.

You know, it's generally a patient will present to a primary care doctor

or an orthopedic surgeon or a general surgeon with a mass that is growing,

something that is changing, or maybe abdominal distension and discomfort.

But like we all learn in medical school,

a good history in physical is the first thing we do.

If this mass has been there for a long time,

it's less likely to be a malignant process or an aggressive malignant process.

If it's rapidly changing, the acuity is obviously there and something needs to be done about it.

But it's very important to stress the history and physical.

I always joke with my trainees that the most important test we order is the history and physical.

With that being said, we generally do recommend plain film imaging,

radiographs, orthogonal views in the extremity particularly,

because that can shed a lot of information in the area of cost containment.

If it's completely radiolucent in an extremity film,

it is very likely to be lipomatous,

well-differentiated liposarcoma at the worst,

versus if it has some calcifications on it,

the acuity is probably there and that it's a synovial sarcoma or potentially a higher grade liposarcoma,

things of that sort.

So radiographs are important and they're inexpensive.

Beyond that, we do think that advanced imaging is important before any biopsy is done.

We generally recommend an MRI in the extremity,

sometimes in the pelvis, but often a CT is adequate.

And if we really suspect that it's a sarcoma,

we prefer getting a chest CT first before any intervention is done.

But if you're seeing the patient in the clinic

and you're going to do a biopsy in the clinic because it's amenable to that,

you can hold off on some of that advanced imaging.

But we certainly recommend getting advanced imaging of the primary before any intervention is done.

As we all will talk about,

the most common site for these metastases is the chest,

and so we do think chest imaging is of paramount importance.

No, I agree, and I think it's always important to remember that,

you know, we hear lots of interesting things and you know,

car doors do not cause hematomas unless you're on blood thinners.

And so, you know, it's very important to always do that history and physical,

because these masses sometimes just get found by car doors.

Otherwise, you know, surgeons go and explore in the middle of a sarcoma,

and if you don't do these right,

I mean, you can get inferior outcomes.

And so, I mean, as we're moving through from the history and physical to imaging,

I think the next most important thing is really an understanding of diagnosis

and grading of these tumors and really what that means.

And I think maybe Dr. Jones can give us a little insight about how they approach that.

Thank you.

So as Dr. Patel mentioned,

these are heterogeneous and a complex group of diseases.

So it's very important to obtain a clear and accurate histological diagnosis prior to starting treatment.

Each histological subtype can have different clinical behavior due to different underlying biology and can also have a different treatment approach.

So it's important to have an experienced pathologist make the diagnosis prior to starting treatment.

The World Health Organization classification system is generally regarded as the standardized publication for classifying these tumors.

and it's very important that newer techniques such as molecular techniques are incorporated into the diagnosis as well.

In terms of grading, the most common grading system that's used is the French,

so-called French grading system, incorporating three grades,

high, intermediate and low, based on tumor differentiation, necrosis and mitotic count.

and the grading system has implications in terms of prognosis.

I think that's really, really important.

And, you know, in the year 2015 with our ability to sequence everybody

and our ability to look at all sorts of molecular markers,

you know, I think we're into a very complex world and a very rare group of tumors.

And so, you know, Jonathan,

what is your goals of molecular testing and how do you incorporate that into your practice?

Good question.

And thank you for the invitation to participate in the panel.

And I agree with, certainly with Shreyas and Robin,

regarding the complexity of sarcomas.

In fact, there's over 200 different types,

if you look at the pathology textbooks.

And I think that molecular testing is underutilized in the world of sarcoma and that it can help in diagnosis.

For instance, there are a number of histologies

that have specific genetic abnormalities such as gene amplification and MDM2 and some of the liposarcomas,

de-differentiated and well-differentiated.

And this testing can not only help make the diagnosis,

but there could also be therapeutic relevance.

For instance, in the era of targeted therapies,

we are now able to pair specific molecular events such as

a mutation in a gene called KIT in GI stromal tumor with a therapy such as imatinib

or sunitinib or regorafenib and be able to really precisely treat patients based on the molecular rearrangements or abnormalities.

And this is particularly pertinent to sarcoma since we have

so many histologic subtypes that have a very high frequency of these molecular abnormalities.

So, Brian, if I could add a few comments with this too.

I think has been well stated.

It's a huge number of different tumors.

And just like you would never classify carcinomas as one disease,

you wouldn't lump breast carcinoma and prostate carcinoma into the same thing.

We do that in sarcomas where we have these different diseases.

We lump together sarcomas because they're so rare and they can have similar presentations but markedly different genetics and different behavior.

And one of the key parts is to make sure,

as Robin was saying, that an expert in sarcoma pathologies reviewing the material,

especially

when it's obtained at a community hospital where pathologists may only

see a few cases of these in the course of their career.

100

The hierarchical testing that they do is based not just on the specimen they have,

101

but also based on the presentation of the patient.

102

So it's also very important that the medical

103

and surgical teams are in communication with the pathologist about the location of the tumor,

104

the behavior of the tumor, and those other aspects.

105

So a multidisciplinary approach is really important.

106

And their testing often looks at the shape of the cells first and where it is located,

107

and then that helps drive other testing like immunistic chemistry and other molecular testing.

108

I think we're still very early in the question of the wide-scale genomic testing that's performed either for research

109

or for clinical commercial purposes right now.

110

In our experience, and I think a lot of the other centers are doing this as well,

111

where we've sequenced large panels of genes,

112

we've seen a disappointingly few number of mutations that we didn't already expect in sarcomas.

113

I think it's still a very important area for research,

114

but personally I'm not yet ready to order huge screening panels for genetic mutations,

115

but instead stay focused, as John was just talking about based on the appearance of the tumor,

116

suspected appearance of the tumor,

117

and the possible mutation types.

118

Dr. Yeah, I'd like to,

119

if I may, an illustrative example is in the pediatric realm of a very practical fusion product,

120

you know, the fusion-associated tumors,

121

rhabdomyosarcoma, where historically it's been either in pediatric realm, conventionally alveolar versus embrinal.

122

And now it's actually fusion-driven,

123

and that's the gold standard.

124

And if there's some Pax-Foxo associated tumor that may have some embryonal features,

125

they're still going to call it alveolar.

126

And it's really that and the clinical trials moving forward through the Children's Inchology Group,

127

et cetera, are all doing this.

128

And I think Synovial and Ewings are following suit with that.

129

So it's really boots on the ground.

130

This is happening today, not just some academic ivory tower concept.

131

And I'd like to just highlight the importance of a multidisciplinary team in making the diagnosis.

132

Andy said, very often it's important to have the clinical features

133

and the radiological features together with the pathology to make the diagnosis.

134

And that's really, really important to highlight.

135

I think it's important to highlight the fact that the one thing that these are all mistaken for are melanomas,

136

and melanomas are, you know, they're mistaken for sarcomas.

137

And if you really make that error,

138

you've altered radically a treatment path for a patient.

139

And this is why having a highly experienced sarcoma pathologist confirming what they're seeing is really that important.

140

And what's very interesting is it's very hard,

141

I believe, to have the discussion we're having today

142

because we're talking about at least 80 different diseases that probably break up in six different categories of each one.

143

And we go from probably one of the best understood tumors on the planet,

144

which is the GI stromal tumor,

145

where we understand what mutations go with what drug,

146

to the undifferentiated pleomorphic sarcoma,

147

where we're still doing lots of clinical trials,

148

which we'll get into later.

TRENDING

Phổ biến

Phương Pháp Shadowing Là Gì?

Shadowing là kỹ thuật học ngôn ngữ có cơ sở khoa học, ban đầu được phát triển cho chương trình đào tạo phiên dịch viên chuyên nghiệp và được phổ biến rộng rãi bởi nhà đa ngôn ngữ học Dr. Alexander Arguelles. Nguyên lý cốt lõi đơn giản nhưng cực kỳ hiệu quả: bạn nghe tiếng Anh của người bản xứ và lặp lại to ngay lập tức — như một "cái bóng" (shadow) đuổi theo người nói với độ trễ chỉ 1–2 giây. Khác với luyện ngữ pháp hay học từ vựng bị động, Shadowing buộc não bộ và cơ miệng phải đồng thời xử lý và tái tạo ngôn ngữ thực tế. Các nghiên cứu khoa học xác nhận phương pháp này cải thiện đáng kể phát âm, ngữ điệu, nhịp điệu, nối âm, kỹ năng nghe và độ lưu loát khi nói — đặc biệt hiệu quả cho người luyện IELTS Speaking và muốn giao tiếp tiếng Anh tự nhiên như người bản ngữ.

ShadowingEnglish.com – Luyện Nói Tiếng Anh Bằng Shadowing

Nói tiếng Anh lưu loát với phương pháp Shadowing — nghe người bản xứ, đọc theo từng câu, rèn phản xạ ngôn ngữ thật sự. Được hàng ngàn người học IELTS tin dùng.

Luyện nói tiếng Anh bằng Shadowing qua video: Accurately Diagnosing the Soft Tissue Sarcoma

Phổ biến

Tại sao nên luyện nói với video này?

Ngữ pháp & Câu diễn đạt trong ngữ cảnh

Các cạm bẫy phát âm phổ biến

Phương Pháp Shadowing Là Gì?

Luyện nói tiếng Anh bằng Shadowing qua video: Accurately Diagnosing the Soft Tissue Sarcoma

Tải Ứng Dụng

Tại sao nên luyện nói với video này?

Ngữ pháp & Câu diễn đạt trong ngữ cảnh

Các cạm bẫy phát âm phổ biến

Phương Pháp Shadowing Là Gì?